This report on global markets for MicroRNA Research Tools, Diagnostics and Therapeutics provides:
- An overview of the global market for microRNA diagnostics and therapeutics, with an analysis of the commercial potential of this research field
- Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
- Examination of the extensive portfolio of miRNA pathway drug candidates, some already in Phase II clinical trials, showing promising clinical data in different areas of medicine, such as cancer, HCV infection, and cardiovascular diseases
- A focus on recent drug candidates, products, deals between different pharmaceutical companies, major participants, and new trends and developments during the last two years
- Forecasts of the future situation and major drawbacks of the miRNA drug development model and possible solutions for these obstacles, especially in context of drug stability and delivery
- Identification of the main markets for RNA therapeutics
- Comprehensive company profiles of major players in the industry.
This report provides an overview of the current state of the microRNA market, focusing specifically on tools, reagents, techniques, diagnostics and therapeutics products. It describes products and tests currently on the market and a detailed analysis of the competitive environments, including new potential trends and markets for novel products and assay development. This study includes information about significant players, trends, and obstacles and other information affecting this market and its different sectors.
REASONS FOR DOING THIS STUDY
The microRNA phenomenon was discovered in the early 1990s. Yet only now scientists and industry insiders are recognizing the importance of this discovery.
The microRNA biogenesis process is essentially the basis for current RNA interference drug discovery and therapeutics research. It led to the development of a very important experimental approach of gene silencing by synthetic double stranded RNA molecules. Today, siRNA tools are among the routine laboratory techniques and essential requirements for scientific proof of concept. Moreover, scientists came to realize that the microRNA silencing pathway is efficient in downregulation of number of target genes, which makes it better in terms of therapeutics development. More importantly, the microRNA expression profile represents critical signatures for biomarker and diagnostic product development.
These facts force diagnostics and therapeutics companies to reconsider microRNA space and to look more closely into microRNA research, diagnostics and therapeutics product development.
Although microRNAs are part of the RNA research market in general, the microRNA sector exhibits specific characteristics and differences in its market participants and competitive landscape.
This report highlights the main segments in the microRNA market: reagents and tools essential for research, current diagnostics products and their development, and drug candidates in the pipelines of different companies. This report also discusses major players, current and future trends, and influences. Drivers and challenges in each segment of this industry are described in detail, including forecasts for the next five years.
SCOPE AND FORMAT
This report is a business tool that can help market players properly evaluate new commercial opportunities in the microRNA reagent, diagnostic and therapeutic submarkets. The geographic scope of this study is global. This market is generally complex and consists of a number of different segments, each of which is affected differently by scientific and technological developments. This report identifies the main factors affecting each segment, and forecasts market growth, future trends, and product development in every major segment of this market.
METHODOLOGY AND INFORMATION SOURCES
Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on drug discovery and already marketed products was conducted. These secondary sources included drug discovery and science–related journals, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. A patent search and analysis were also conducted.
In a second phase, a series of semi–structured interviews was conducted with company representatives, bench scientists, marketing representatives, and other personnel at biotechnology and pharmaceutical companies. Other sources included academics, technology, and consulting companies. Subsequent analysis of the documents and interview notes was iterative.
This report is intended for business development professionals, entrepreneurs, and other investors who need to fully understand and properly evaluate each segment in the market for microRNA research tools, diagnostics and therapeutics. It provides insights into the market position of major companies, and shows new opportunities otherwise overlooked or less known to the business community.
Dr. Marianna Tcherpakov has more than seven years of experience as a bench scientist specializing in biochemistry, cell biology, and industrial assay development. She has contributed to a number of scientific publications and holds several patents. She has expertise as an assay development scientist and is familiar with different research field trends and likely future developments.